NCT04629248 (MAJESTY) is a Phase 3 clinical trial of Obinutuzumab in Primary Membranous Nephropathy, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT04629248?

NCT04629248 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT04629248?

Interventions in NCT04629248: Obinutuzumab, Tacrolimus, Methylprednisolone, Acetaminophen, Diphenhydramine.

What condition does NCT04629248 study?

NCT04629248 studies Primary Membranous Nephropathy.

Is NCT04629248 still recruiting?

NCT04629248 is currently active, enrolled. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT04629248: MAJESTY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Active, enrolled Phase 3 Last updated 7 April 2026

What this trial tests

Phase 3 trial testing Obinutuzumab in Primary Membranous Nephropathy in 142 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

25 June 2021

Primary endpoint
22 December 2025

21 December 2027

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	142
Start date	25 June 2021
Primary completion	22 December 2025
Estimated completion	21 December 2027
Sites	50 locations across France, Italy, Russia, Israel, Poland, Argentina, China, Spain

Drugs / interventions tested

Obinutuzumab — full drug profile →
Tacrolimus
Methylprednisolone (methylprednisolone) — full drug profile →
Acetaminophen (Paracetamol) — full drug profile →
Diphenhydramine (diphenhydramine) — full drug profile →

Conditions studied

Primary Membranous Nephropathy — all drugs for Primary Membranous Nephropathy →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

Adults 18 to 75, any sex, with Primary Membranous Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children.
Dossier C, Bonneric S, Baudouin V, Kwon T, et al · · 2023 · cited 42× · PMID 37678236 · DOI 10.2215/cjn.0000000000000288
Novel Treatments Paradigms: Membranous Nephropathy.
Rojas-Rivera JE, Ortiz A, Fervenza FC. · · 2023 · cited 37× · PMID 36938069 · DOI 10.1016/j.ekir.2022.12.011
Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives.
Hartinger JM, Kratky V, Hruskova Z, Slanar O, et al · · 2022 · cited 30× · PMID 36420256 · DOI 10.3389/fimmu.2022.1024068
Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases.
Hudson R, Rawlings C, Mon SY, Jefferis J, et al · · 2022 · cited 26× · PMID 35392837 · DOI 10.1186/s12882-022-02761-3
Future landscape for the management of membranous nephropathy.
Caravaca-Fontán F, Yandian F, Fervenza FC. · · 2023 · cited 21× · PMID 37529655 · DOI 10.1093/ckj/sfad041
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy.
Rojas-Rivera J, Fervenza FC, Ortiz A. · · 2022 · cited 21× · PMID 34932208 · DOI 10.1007/s40265-021-01656-1
Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy.
Su X, Wu B, Tie X, Guo X, et al · · 2024 · cited 19× · PMID 39156138 · DOI 10.1016/j.ekir.2024.05.004
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.
Teisseyre M, Allinovi M, Audard V, Cremoni M, et al · · 2025 · cited 12× · PMID 40225374 · DOI 10.1016/j.ekir.2024.12.012

Verify or expand the search:

Other trials of Obinutuzumab

Trials testing the same drug.

NCT07003295 — Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease R · Phase 2 · recruiting
NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g · Phase 2 · not yet recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
NCT07480850 — Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma · Phase 2 · active not recruiting
NCT07261163 — Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma · Phase 2 · not yet recruiting

Other recruiting trials for Primary Membranous Nephropathy

Currently open trials in the same condition.

NCT07204275 — A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropat · Phase 2, PHASE3 · recruiting
NCT07157787 — Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) · Phase 2 · recruiting
NCT06962800 — A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropath · Phase 3 · recruiting
NCT06642909 — A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy · Phase 2 · active not recruiting
NCT06893328 — A Real World Study About PMN · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04629248 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04629248.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing